NOVEMBER 5, 2021
Revlon Reports Third Quarter 2021 Results
Results Reflect Continued Top-Line Growth in All Reporting Segments Company Continues to Execute on Strategic Pillars, Driving Highest As Reported Third Quarter EBITDA in Five Years
AUGUST 26, 2021
Revlon Announces Thomas Cho as its Chief Supply Chain Officer
Revlon, Inc. recently announced the hire of Mr. Thomas Cho as Chief Supply Chain Officer. In this position, Mr. Cho will be responsible for Revlon’s end to end Global Supply Chain Operations, including supply chain strategy, planning, procurement, manufacturing, engineering, distribution and logistics for the Company’s diverse brand portfolio across all channels and geographies.
APRIL 5, 2022
Vericast to Invest in Digital Marketing Technologies, Hire 250+ to Support Growth
Investments in machine learning, omnichannel platform, universal coupons and more
JANUARY 13, 2022
Essential Federal Credit Union Supercharges Member Digital Engagement with Vericast’s Account Advisor Powered by Ignite Sales
Account Advisor enables Essential FCU to provide a deeper, consistent, and differentiated member experience
NOVEMBER 15, 2022
Vericast Reports Strong Third Quarter Results
Vericast is announcing highlights of its third quarter 2021 performance and its outlook for the year ahead. The company’s consolidated net revenues decreased 0.5% compared to 2020, while total adjusted EBITDA increased 10.2%.
JANUARY 18, 2022
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
SIGA Technologies, Inc. , a commercial-stage pharmaceutical company focused on the health security market, announced today that it will be participating in Edison Group’s Open House Event, scheduled to take place virtually this month.
JANUARY 10, 2022
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications
JANUARY 13, 2022
vTv Therapeutics Shares Updated Corporate Presentation
VTVT, a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population.
November 09, 2021
vTv Therapeutics Announces 2021 Third Quarter Financial Results and Provides Corporate Update
VTVT today reported financial results for the third quarter ended September 30, 2021, and provided an update on the progress of its clinical programs.